These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 24914850)
1. [Economic features of active surveillance]. Huguet J; Musquera M; Ribal MJ; Alcaraz A Arch Esp Urol; 2014 Jun; 67(5):509-13. PubMed ID: 24914850 [TBL] [Abstract][Full Text] [Related]
2. The economics of active surveillance for prostate cancer. Dall'Era MA Curr Opin Urol; 2013 May; 23(3):278-82. PubMed ID: 23449496 [TBL] [Abstract][Full Text] [Related]
3. Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer. Laviana AA; Ilg AM; Veruttipong D; Tan HJ; Burke MA; Niedzwiecki DR; Kupelian PA; King CR; Steinberg ML; Kundavaram CR; Kamrava M; Kaplan AL; Moriarity AK; Hsu W; Margolis DJ; Hu JC; Saigal CS Cancer; 2016 Feb; 122(3):447-55. PubMed ID: 26524087 [TBL] [Abstract][Full Text] [Related]
4. Economic analysis of active surveillance for localized prostate cancer. Kim S; Dall'Era MA; Evans CP Curr Opin Urol; 2012 May; 22(3):247-53. PubMed ID: 22388666 [TBL] [Abstract][Full Text] [Related]
5. Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis. Hayes JH; Ollendorf DA; Pearson SD; Barry MJ; Kantoff PW; Lee PA; McMahon PM Ann Intern Med; 2013 Jun; 158(12):853-60. PubMed ID: 23778902 [TBL] [Abstract][Full Text] [Related]
6. A comprehensive analysis of cost of an active surveillance cohort compared to radical prostatectomy as primary treatment for prostate cancer. Pozo C; Hernández V; Capitán C; de la Peña E; Fernández-Conejo G; Martínez MDM; Del Riego S; Pérez-Fernández E; Llorente C World J Urol; 2019 Jul; 37(7):1297-1303. PubMed ID: 30276542 [TBL] [Abstract][Full Text] [Related]
7. Managing localized prostate cancer by radical prostatectomy or watchful waiting: Cost analysis of a randomized trial (SPCG-4). Andersson SO; Andrén O; Lyth J; Stark JR; Henriksson M; Adami HO; Carlsson P; Johansson JE Scand J Urol Nephrol; 2011 Apr; 45(3):177-83. PubMed ID: 21265595 [TBL] [Abstract][Full Text] [Related]
8. A decision analysis comparing 3 active surveillance protocols for the treatment of patients with low-risk prostate cancer. White C; Nimeh T; Gazelle GS; Weinstein MC; Loughlin KR Cancer; 2019 Mar; 125(6):952-962. PubMed ID: 30561761 [TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of active surveillance compared to watchful waiting and radical prostatectomy for low risk localised prostate cancer. Lao C; Edlin R; Rouse P; Brown C; Holmes M; Gilling P; Lawrenson R BMC Cancer; 2017 Aug; 17(1):529. PubMed ID: 28789623 [TBL] [Abstract][Full Text] [Related]
10. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow. Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849 [TBL] [Abstract][Full Text] [Related]
11. Cost comparison between watchful waiting with active surveillance and active treatment of clinically localized prostate cancer. Corcoran AT; Peele PB; Benoit RM Urology; 2010 Sep; 76(3):703-7. PubMed ID: 20381846 [TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of treatments for patients with localized prostate cancer in Europe: a systematic review. Becerra V; Ávila M; Jimenez J; Cortes-Sanabria L; Pardo Y; Garin O; Pont A; Alonso J; Cots F; Ferrer M; BMC Health Serv Res; 2016 Oct; 16(1):541. PubMed ID: 27716267 [TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Active Surveillance, Radical Prostatectomy and External Beam Radiotherapy for Localized Prostate Cancer: An Analysis of the ProtecT Trial. Sharma V; Wymer KM; Borah BJ; Barocas DA; Thompson RH; Karnes RJ; Boorjian SA J Urol; 2019 Nov; 202(5):964-972. PubMed ID: 31112105 [TBL] [Abstract][Full Text] [Related]
15. Maximizing resources in the local treatment of prostate cancer: A summary of cost-effectiveness studies. Muralidhar V; Nguyen PL Urol Oncol; 2017 Feb; 35(2):76-85. PubMed ID: 27473636 [TBL] [Abstract][Full Text] [Related]
16. Active surveillance for prostate cancer compared with immediate treatment: an economic analysis. Keegan KA; Dall'Era MA; Durbin-Johnson B; Evans CP Cancer; 2012 Jul; 118(14):3512-8. PubMed ID: 22180322 [TBL] [Abstract][Full Text] [Related]
17. [Treatment costs of localized prostate cancer in Germany : Economic results from the HAROW observational study]. Reinhold T; Dornquast C; Börgermann C; Weißbach L Urologe A; 2016 Dec; 55(12):1573-1585. PubMed ID: 27822603 [TBL] [Abstract][Full Text] [Related]
18. Words of wisdom. Re: Active surveillance for prostate cancer compared with immediate treatment: an economic analysis. Klaassen Z; Wyatt B; Moses KA; Terris MK Eur Urol; 2013 Nov; 64(5):855. PubMed ID: 24112612 [No Abstract] [Full Text] [Related]
19. An economic analysis of conservative management versus active treatment for men with localized prostate cancer. Perlroth DJ; Bhattacharya J; Goldman DP; Garber AM J Natl Cancer Inst Monogr; 2012 Dec; 2012(45):250-7. PubMed ID: 23271781 [TBL] [Abstract][Full Text] [Related]
20. How does initial treatment choice affect short-term and long-term costs for clinically localized prostate cancer? Snyder CF; Frick KD; Blackford AL; Herbert RJ; Neville BA; Carducci MA; Earle CC Cancer; 2010 Dec; 116(23):5391-9. PubMed ID: 20734396 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]